ASX Penny Stocks To Watch In January 2025

In This Article:

As 2024 closed, the Australian market experienced a downturn, with the ASX finishing on a two-day decline, highlighting profit-taking across most sectors. Despite this broader market pullback, investors continue to seek opportunities in undervalued areas such as penny stocks. Though often considered niche or outdated, these smaller or newer companies can offer significant growth potential when supported by strong financials.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.765

A$140.36M

★★★★☆☆

LaserBond (ASX:LBL)

A$0.56

A$65.64M

★★★★★★

SHAPE Australia (ASX:SHA)

A$2.88

A$238.78M

★★★★★★

Helloworld Travel (ASX:HLO)

A$1.955

A$318.31M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.51

A$316.27M

★★★★★☆

Navigator Global Investments (ASX:NGI)

A$1.72

A$842.94M

★★★★★☆

MaxiPARTS (ASX:MXI)

A$1.88

A$103.99M

★★★★★★

SKS Technologies Group (ASX:SKS)

A$1.59

A$205.65M

★★★★★★

Vita Life Sciences (ASX:VLS)

A$2.00

A$112.19M

★★★★★★

Servcorp (ASX:SRV)

A$4.90

A$483.46M

★★★★☆☆

Click here to see the full list of 1,052 stocks from our ASX Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Imugene

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Imugene Limited is a clinical-stage immuno-oncology company in Australia focused on developing immunotherapies to activate the immune system of cancer patients, with a market cap of A$275.18 million.

Operations: The company's revenue is derived entirely from the research, development, and commercialisation of health technologies, amounting to A$4.97 million.

Market Cap: A$275.18M

Imugene Limited, with a market cap of A$275.18 million, is a clinical-stage company focused on immunotherapies but remains pre-revenue with A$5 million in revenue. The company is unprofitable and has experienced increasing losses over the past five years. Despite having no debt and short-term assets of A$113 million covering both short-term (A$29.3M) and long-term liabilities (A$3.8M), Imugene faces challenges with less than one year of cash runway. Recent board changes include the resignation of Jens Eckstein as a non-executive director, highlighting potential shifts in strategic direction amidst financial constraints.

ASX:IMU Debt to Equity History and Analysis as at Jan 2025
ASX:IMU Debt to Equity History and Analysis as at Jan 2025

Latin Resources

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Latin Resources Limited is engaged in the exploration and development of mining projects across Australia, Peru, Argentina, and Brazil with a market capitalization of A$448.23 million.